Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea

A3L31 Study Group

doi:10.1016/j.vaccine.2017.05.062

Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea

A3L31 Study Group

Department of Pediatrics

Samsung Medical Center, Sungkyunkwan university
Jeonbuk National University
Catholic University of Korea
Catholic Univ. of Korea Coll. Med.
Sanofi-Aventis
Sanofi Pasteur
Korea University
Yonsei University Mirae Campus
Dankook University
Daejeon St. Mary's Hospital
Kyung Hee University
The Catholic University of Korea Incheon St. Mary's Hospital
Changwon Fatima Hospital
Korea Institute of Radiological and Medical Sciences
Hanil General Hospital
Pusan National University
Seoul National University
Wonkwang University
Yonsei University
Ewha Womans University

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Original language	English
Pages (from-to)	4022-4028
Number of pages	7
Journal	Vaccine
Volume	35
Issue number	32
DOIs	https://doi.org/10.1016/j.vaccine.2017.05.062
State	Published - 13 Jul 2017

Bibliographical note

Funding Information:
This study was supported by Sanofi Pasteur, Lyon, France.

Funding Information:
The authors acknowledge the study personnel for the conduct of the study and also all enrolled infants and parents/legal guardian(s) for their participation. This manuscript was prepared with the assistance of a professional medical writer, Dr Andrew Lane (Lane Medical Writing), in accordance with the European Medical Writers Association guidelines and Good Publication Practice. This study was funded by Sanofi Pasteur.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.vaccine.2017.05.062

Cite this

@article{1ab12f2f1b5b4071a3404144d1f5a71c,

title = "Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea",

author = "\{A3L31 Study Group\} and Kim, \{Yae Jean\} and Jo, \{Dae Sun\} and Kim, \{Hyun Hee\} and Kang, \{Jin Han\} and Kim, \{Hee Soo\} and Joon Bang and Yongho Oh and Kim, \{Yun Kyung\} and Emmanuel Vidor and Kim, \{Hwang Min\} and Shin, \{Son Moon\} and Lee, \{Kyung Yil\} and Cha, \{Sung Ho\} and Ma, \{Sang Hyuk\} and Kim, \{Dong Ho\} and Jin Lee and Park, \{Su Eun\} and Hyunju Lee and Kim, \{Jong Duk\} and Kim, \{Ki Hwan\} and Kim, \{Kyung Hyo\} and Kim, \{Jong Hyun\}",

note = "Funding Information: This study was supported by Sanofi Pasteur, Lyon, France. Funding Information: The authors acknowledge the study personnel for the conduct of the study and also all enrolled infants and parents/legal guardian(s) for their participation. This manuscript was prepared with the assistance of a professional medical writer, Dr Andrew Lane (Lane Medical Writing), in accordance with the European Medical Writers Association guidelines and Good Publication Practice. This study was funded by Sanofi Pasteur. ",

year = "2017",

month = jul,

day = "13",

doi = "10.1016/j.vaccine.2017.05.062",

language = "English",

volume = "35",

pages = "4022--4028",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "32",

}

TY - JOUR

T1 - Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea

AU - A3L31 Study Group

AU - Kim, Yae Jean

AU - Jo, Dae Sun

AU - Kim, Hyun Hee

AU - Kang, Jin Han

AU - Kim, Hee Soo

AU - Bang, Joon

AU - Oh, Yongho

AU - Kim, Yun Kyung

AU - Vidor, Emmanuel

AU - Kim, Hwang Min

AU - Shin, Son Moon

AU - Lee, Kyung Yil

AU - Cha, Sung Ho

AU - Ma, Sang Hyuk

AU - Kim, Dong Ho

AU - Lee, Jin

AU - Park, Su Eun

AU - Lee, Hyunju

AU - Kim, Jong Duk

AU - Kim, Ki Hwan

AU - Kim, Kyung Hyo

AU - Kim, Jong Hyun

N1 - Funding Information: This study was supported by Sanofi Pasteur, Lyon, France. Funding Information: The authors acknowledge the study personnel for the conduct of the study and also all enrolled infants and parents/legal guardian(s) for their participation. This manuscript was prepared with the assistance of a professional medical writer, Dr Andrew Lane (Lane Medical Writing), in accordance with the European Medical Writers Association guidelines and Good Publication Practice. This study was funded by Sanofi Pasteur.

PY - 2017/7/13

Y1 - 2017/7/13

UR - https://www.scopus.com/pages/publications/85020543272

U2 - 10.1016/j.vaccine.2017.05.062

DO - 10.1016/j.vaccine.2017.05.062

M3 - Article

C2 - 28629923

AN - SCOPUS:85020543272

SN - 0264-410X

VL - 35

SP - 4022

EP - 4028

JO - Vaccine

JF - Vaccine

IS - 32

ER -

Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this